0001209191-19-002674.txt : 20190107
0001209191-19-002674.hdr.sgml : 20190107
20190107205120
ACCESSION NUMBER: 0001209191-19-002674
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190107
FILED AS OF DATE: 20190107
DATE AS OF CHANGE: 20190107
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Manning Paul B
CENTRAL INDEX KEY: 0001494695
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38529
FILM NUMBER: 19514541
MAIL ADDRESS:
STREET 1: 200 GARRETT STREET SUITE S
CITY: CHARLOTTESVILLE
STATE: VA
ZIP: 22902
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Verrica Pharmaceuticals Inc.
CENTRAL INDEX KEY: 0001660334
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 463137900
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10 NORTH HIGH STREET
STREET 2: SUITE 200
CITY: WEST CHESTER
STATE: PA
ZIP: 19380
BUSINESS PHONE: 484-453-3300
MAIL ADDRESS:
STREET 1: 10 NORTH HIGH STREET
STREET 2: SUITE 200
CITY: WEST CHESTER
STATE: PA
ZIP: 19380
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-01-07
0
0001660334
Verrica Pharmaceuticals Inc.
VRCA
0001494695
Manning Paul B
200 GARRETT STREET, SUITE S
CHARLOTTESVILLE
VA
22902
1
0
1
0
Common Stock
2019-01-07
4
P
0
12775
10.41
A
8035658
D
Common Stock
2019-01-07
4
P
0
20116
11.55
A
8055774
D
Common Stock
2019-01-07
4
P
0
2734
11.99
A
8058508
D
Common Stock
2019-01-07
4
P
0
4258
10.41
A
1299602
I
See Footnote
Common Stock
2019-01-07
4
P
0
6706
11.55
A
1306308
I
See Footnote
Common Stock
2019-01-07
4
P
0
911
11.99
A
1307219
I
See Footnote
Common Stock
256634
I
See Footnote
The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $9.87 to $10.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Consists of 7,754,783 shares of common stock held by Mr. Manning and 280,875 shares of common stock held by Mr. Manning jointly with his spouse.
The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $10.98 to $11.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Consists of 7,754,783 shares of common stock held by Mr. Manning and 300,991 shares of common stock held by Mr. Manning jointly with his spouse.
The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $11.98 to $12.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Consists of 7,754,783 shares of common stock held by Mr. Manning and 303,725 shares of common stock held by Mr. Manning jointly with his spouse.
The shares are held directly by BKB Growth Investments, LLC ("BKB"). The Reporting Person is a co-manager of BKB and has sole voting and investment power with respect to the shares held by BKB.
The shares are held directly by PBM Capital Investments, LLC ("PBMCI"). The Reporting Person is President and CEO of PBMCI and has sole voting and investment power with respect to the shares held by PBMCI.
/s/ Mark Ballantyne, Attorney-in-Fact
2019-01-07